While GLP-1s dominated the obesity narrative, the next wave of innovation is focused on novel mechanisms. Arrowhead's significant fundraise for its siRNA drug highlights investor enthusiasm for approaches that offer complementary benefits, such as preserving muscle mass, signaling a new chapter in obesity treatment.

Instead of the traditional 'disease-target-drug' approach, Soleil finds compounds that create a desired cellular change first. Only after identifying a promising, well-tolerated molecule with a known cellular mechanism do they use bioinformatics to determine which disease and patient population it's best suited for.

Neurocrine's move from neuroscience into obesity is not a random leap but a calculated pivot. The company is leveraging its deep, historical expertise in the CRF biological system, a shared mechanism between the fields, to de-risk its entry into a new, high-growth therapeutic area.

Unlike ventures in established biological pathways, startups tackling novel biology must first prove a specific drug product can work. The primary question isn't about the platform's potential applications but whether a single, tangible therapeutic is viable. Focusing on a broad platform too early is a mistake.

Beyond identifying potential drug targets, Moonwalk uses AI to analyze why some targets succeed in animal models while others fail. By feeding its proprietary biological data into large models, the team gains insights into pathways and mechanisms. This deeper understanding helps prioritize candidates and allows the AI to suggest novel, related targets.

Acknowledging its late entry into the crowded obesity market, Protagonist consulted key opinion leaders to define the ideal drug profile: an oral "triple G" agonist. By using its peptide platform to build exactly what experts requested, the company aims to leapfrog competitors with a best-in-class product rather than an incremental improvement.

A key differentiator for Moonwalk's long-acting siRNA therapy is its potential for highly infrequent dosing—quarterly or even semi-annually. This contrasts sharply with the daily pills or weekly injections for current obesity treatments. For a chronic condition, this dramatic improvement in convenience and adherence is a powerful competitive advantage.

Moonwalk's discovery engine combines broad, large-scale analysis of public genetic data from millions of individuals with deep, proprietary epigenetic data generated from fat cell samples. This unique data-layering approach allows them to identify novel causal links to obesity that other researchers may have missed.

Instead of creating a more potent version of popular GLP-1 obesity drugs, Moonwalk is developing a therapy with a different biological mechanism. Their goal is to offer meaningful weight loss but with fewer side effects like muscle loss and GI issues, and with less frequent dosing (once every six months).